NCT01566591Unknown不适用
A Prospective, Double Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the H1-Coil Deep Transcranial Magnetic Stimulation (TMS) in Conjunction With Mood Stabilizers in Subjects With Bipolar Depression
适应症
试验速览
- 阶段
- 不适用
- 发起方
- Brainsway
- 入组人数
- 120
- 试验地点
- 21
- 主要终点
- HDRS-21 Score measured by change from baseline.
研究概览
简要总结
The purpose of the study is to evaluate the efficacy and safety of H1-Coil deep brain rTMS in subjects with bipolar depression, taking mood stabilizers and previously unsuccessfully treated with antidepressant medications.
详细描述
This is a multi center, randomized, double blind study to evaluate the efficacy and safety of H1-Coil deep brain rTMS in subjects with bipolar depression, taking mood stabilizers and previously unsuccessfully treated with antidepressant medications. The study is designed for a period of 8 weeks of which up to 3 weeks subjects will be tapered down from their medications and treated for 5 weeks. Two follow up visits will be performed at week 6 and 8 after the last TMS treatment. Mood and mental status will be closely monitored with standard psychological scales and assessments
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 22 Years 至 68 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Outpatients
- •patients suffering from an episode of bipolar depression (BP1 or BP2) according to DSM IV, with the additional requirement of duration for the current episode ≥ 4 weeks and CGI ≥
- •Men and Women Ages 22-68 years.
- •Negative answers on safety screening questionnaire for transcranial magnetic stimulation.
- •Taking mood stabilizing medication (e.g., Lithium, Lamictal, Tegretol, Topamax, etc.) at a therapeutic dose or atypical antipsychotic medication which was prescribed as mood stabilizers by their treating physician, except for Leponex (Clozapine). According to the treating physician the patient is compliant with taking the mood-stabilizing medication.
排除标准
- •patients suffering from other diagnoses on axis 1 such as schizophrenia , or suffering from psychotic depression in current episode.
- •Diagnosed as suffering from Severe Borderline Personality Disorder or hospitalized due to exacerbation related to of borderline personality disorder. Subjects suffering from any other Severe Personality Disorder will also be excluded.
- •Present suicidal risk as assessed by the investigator
- •Patients with a bipolar cycle of less than 30 days.
- •History of epilepsy or seizure (EXCEPT those therapeutically induced by ECT ) or history of such in first degree relatives.
- •Increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or history of significant head trauma with loss of consciousness for greater than or equal to 5 minutes.
- •History of head injury.
- •History of any metal in the head (outside the mouth).
- •Metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines, implanted neurostimulators, intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or implanted medical pumps.
- •Hearing loss.
- •Individuals with a significant neurological disorder or insult including, but not limited to:
- •Any condition likely to be associated with increased intracranial pressure
- •Space occupying brain lesion
- •History of cerebrovascular accident
- •Transient ischemic attack within two years
- •Cerebral aneurysm
- •Parkinson's disease
- •Huntington's chorea
- •Multiple sclerosis
- •Current History of substance abuse including alcoholism or history of substance abuse including alcoholism within the past 6 months (except nicotine and caffeine).
- •Inadequate communication with the patient.
- •Under custodial care.
- •Participation currently in another clinical study or enrolled in another clinical study within 30 days prior to this study.
- •Participants who suffer from an unstable physical disease such as high blood pressure or acute, unstable cardiac disease
- •Use of fluoxetine within 6 weeks of the baseline visit
- •Use of a Monoamine Oxidase Inhibitor (MAOI) within 2 weeks of the baseline visit
- •Current use of antidepressant medications during the course of the trial.
- •Current use of Leponex (Clozapine).
- •Previous treatment with TMS
- •Women who are breast-feeding
- •Known or suspected pregnancy
- •Women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse.
结局指标
主要结局
HDRS-21 Score measured by change from baseline.
时间窗: 6 weeks from baseline
次要结局
- Clinical antidepressant remission rate at the 6-week visit(6 weeks from baseline)
研究者
研究点 (21)
Loading locations...
相似试验
Unknown
不适用
Double Blind Randomized Controlled, H1 Coil In Subjects With Bipolar DepressionBipolar DepressionNCT00657735Shalvata Mental Health Center50
Unknown
不适用
Tolerability, Safety and Efficacy of the H1-coil Deep Transcranial Magnetic Stimulation in Subjects With Negative Symptoms and Cognitive Deficits of SchizophreniaSchizophreniaNCT00685321Shalvata Mental Health Center45
已完成
不适用
Deep rTMS for Treatment-Resistant Late-life DepressionMajor Depressive DisorderNCT01860157Centre for Addiction and Mental Health58
Unknown
不适用
A Double Blind Sham-controled Study to Evaluate the Influence of Low Frequency Repetitive Transcranial Stimulation (r-TMS) on Motor and Cognitive Measurements in Patients With Asymmetric Parkinson's DiseaseAsymmetric Parkinson's DiseaseNCT01367782Sheba Medical Center51
Unknown
不适用
Evaluation of the H1-Coil TMS- Double Blind Placebo Controlled Study in Adolescent Patients Suffering From Major DepressionDepressionNCT03541707Shalvata Mental Health Center52